Intra-Cellular Therapies, Inc. (NASDAQ:ITCI) Shares Sold by American Century Companies Inc.

American Century Companies Inc. cut its position in Intra-Cellular Therapies, Inc. (NASDAQ:ITCI) by 50.5% during the second quarter, HoldingsChannel.com reports. The fund owned 268,983 shares of the biopharmaceutical company’s stock after selling 273,930 shares during the period. American Century Companies Inc.’s holdings in Intra-Cellular Therapies were worth $18,423,000 at the end of the most recent reporting period.

Other institutional investors have also recently made changes to their positions in the company. Oak Ridge Investments LLC acquired a new stake in shares of Intra-Cellular Therapies in the second quarter worth approximately $811,000. Perceptive Advisors LLC acquired a new stake in shares of Intra-Cellular Therapies in the fourth quarter worth approximately $7,735,000. SG Americas Securities LLC boosted its stake in shares of Intra-Cellular Therapies by 962.7% in the second quarter. SG Americas Securities LLC now owns 48,778 shares of the biopharmaceutical company’s stock worth $3,341,000 after acquiring an additional 44,188 shares during the last quarter. Schroder Investment Management Group boosted its stake in shares of Intra-Cellular Therapies by 36.7% in the fourth quarter. Schroder Investment Management Group now owns 779,823 shares of the biopharmaceutical company’s stock worth $55,851,000 after acquiring an additional 209,331 shares during the last quarter. Finally, Clearbridge Investments LLC boosted its stake in shares of Intra-Cellular Therapies by 12.3% in the first quarter. Clearbridge Investments LLC now owns 1,744,551 shares of the biopharmaceutical company’s stock worth $120,723,000 after acquiring an additional 191,416 shares during the last quarter. 92.33% of the stock is owned by institutional investors and hedge funds.

Intra-Cellular Therapies Stock Up 0.8 %

ITCI opened at $77.61 on Friday. Intra-Cellular Therapies, Inc. has a 52 week low of $45.50 and a 52 week high of $84.89. The business has a fifty day simple moving average of $75.67 and a 200-day simple moving average of $71.44. The firm has a market cap of $8.19 billion, a P/E ratio of -66.91 and a beta of 1.00.

Intra-Cellular Therapies (NASDAQ:ITCI) last announced its earnings results on Wednesday, August 7th. The biopharmaceutical company reported ($0.16) EPS for the quarter, beating analysts’ consensus estimates of ($0.19) by $0.03. The company had revenue of $161.40 million during the quarter, compared to analysts’ expectations of $157.74 million. Intra-Cellular Therapies had a negative return on equity of 11.48% and a negative net margin of 14.93%. Intra-Cellular Therapies’s revenue for the quarter was up 45.7% on a year-over-year basis. During the same period last year, the business posted ($0.45) EPS. Sell-side analysts expect that Intra-Cellular Therapies, Inc. will post -0.59 earnings per share for the current year.

Insider Transactions at Intra-Cellular Therapies

In related news, EVP Mark Neumann sold 18,714 shares of Intra-Cellular Therapies stock in a transaction that occurred on Friday, August 16th. The shares were sold at an average price of $75.08, for a total value of $1,405,047.12. Following the completion of the transaction, the executive vice president now owns 29,700 shares in the company, valued at $2,229,876. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available at the SEC website. In related news, EVP Mark Neumann sold 18,714 shares of Intra-Cellular Therapies stock in a transaction on Friday, August 16th. The stock was sold at an average price of $75.08, for a total value of $1,405,047.12. Following the completion of the transaction, the executive vice president now directly owns 29,700 shares in the company, valued at $2,229,876. The transaction was disclosed in a document filed with the SEC, which is available at the SEC website. Also, Director Rory B. Riggs sold 4,462 shares of the company’s stock in a transaction dated Monday, June 24th. The stock was sold at an average price of $75.57, for a total value of $337,193.34. Following the sale, the director now owns 116,600 shares in the company, valued at approximately $8,811,462. The disclosure for this sale can be found here. Over the last quarter, insiders have sold 179,778 shares of company stock valued at $13,374,538. 3.40% of the stock is currently owned by corporate insiders.

Analyst Ratings Changes

A number of equities analysts recently commented on the company. Piper Sandler upgraded Intra-Cellular Therapies from a “neutral” rating to an “overweight” rating and lifted their price objective for the stock from $68.00 to $92.00 in a research report on Friday, September 6th. UBS Group reduced their price objective on Intra-Cellular Therapies from $83.00 to $79.00 and set a “neutral” rating on the stock in a research report on Thursday, August 8th. Cantor Fitzgerald reiterated an “overweight” rating and set a $130.00 price objective on shares of Intra-Cellular Therapies in a research report on Monday, September 16th. Needham & Company LLC reiterated a “buy” rating and set a $100.00 price objective on shares of Intra-Cellular Therapies in a research report on Wednesday, August 7th. Finally, The Goldman Sachs Group reduced their price objective on Intra-Cellular Therapies from $77.00 to $74.00 and set a “neutral” rating on the stock in a research report on Thursday, August 8th. Three equities research analysts have rated the stock with a hold rating and ten have assigned a buy rating to the company’s stock. Based on data from MarketBeat, Intra-Cellular Therapies has a consensus rating of “Moderate Buy” and an average price target of $96.58.

Intra-Cellular Therapies Company Profile

Intra-Cellular Therapies, Inc, a biopharmaceutical company, focuses on the discovery, clinical development, and commercialization of small molecule drugs that address medical needs primarily in neuropsychiatric and neurological disorders by targeting intracellular signaling mechanisms in the central nervous system (CNS) in the United States.